Spyridon Megremis1, Katarzyna Niespodziana2, Clarissa Cabauatan2, Paraskevi Xepapadaki3, Marek L Kowalski4, Tuomas Jartti5, Claus Bachert6, Susetta Finotto7, Peter West1, Sofia Stamataki8, Anna Lewandowska-Polak4, Heikki Lukkarinen5, Nan Zhang6, Theodor Zimmermann7, Frank Stolz9, Angela Neubauer9, Mübeccel Akdis10, Evangelos Andreakos11, Rudolf Valenta2,12, Nikolaos G Papadopoulos1,2. 1. Division of Infection, Immunity and Respiratory Medicine and. 2. Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria. 3. Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece. 4. Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, Lodz, Poland. 5. Department of Paediatrics, Turku University Hospital, University of Turku, Turku, Finland. 6. Upper Airways Research Laboratory, Ghent University, Ghent, Belgium. 7. Department of Molecular Pneumology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. 8. Athens General Children's Hospital "Pan & Aglaia Kyriakou," Athens, Greece. 9. Biomay, AG, Vienna, Austria. 10. Swiss Institute of Allergy and Asthma Research, University of Zurich, Zurich, Switzerland. 11. Biomedical Research Foundation, Academy of Athens, Athens, Greece; and. 12. NRC Institute of Immunology FMBA of Russia, Moscow, Russia.
Abstract
Rationale: Rhinoviruses (RVs) are major triggers of common cold and acute asthma exacerbations. RV species A, B, and C may have distinct clinical impact; however, little is known regarding RV species-specific antibody responses in health and asthma. Objectives: To describe and compare total and RV species-specific antibody levels in healthy children and children with asthma, away from an acute event. Methods: Serum samples from 163 preschool children with mild to moderate asthma and 72 healthy control subjects from the multinational Predicta cohort were analyzed using the recently developed PreDicta RV antibody chip.Measurements and Main Results: RV antibody levels varied, with RV-C and RV-A being higher than RV-B in both groups. Compared with control subjects, asthma was characterized by significantly higher levels of antibodies to RV-A and RV-C, but not RV-B. RV antibody levels positively correlated with the number of common colds over the previous year in healthy children, and wheeze episodes in children with asthma. Antibody levels also positively correlated with asthma severity but not with current asthma control.Conclusions: The variable humoral response to RV species in both groups suggests a differential infectivity pattern between RV species. In healthy preschoolers, RV antibodies accumulate with colds. In asthma, RV-A and RV-C antibodies are much higher and further increase with disease severity and wheeze episodes. Higher antibody levels in asthma may be caused by a compromised innate immune response, leading to increased exposure of the adaptive immune response to the virus. Importantly, there is no apparent protection with increasing levels of antibodies.
Rationale: Rhinoviruses (RVs) are major triggers of common cold and acute asthma exacerbations. RV species A, B, and C may have distinct clinical impact; however, little is known regarding RV species-specific antibody responses in health and asthma. Objectives: To describe and compare total and RV species-specific antibody levels in healthy children and children with asthma, away from an acute event. Methods: Serum samples from 163 preschool children with mild to moderate asthma and 72 healthy control subjects from the multinational Predicta cohort were analyzed using the recently developed PreDicta RV antibody chip.Measurements and Main Results: RV antibody levels varied, with RV-C and RV-A being higher than RV-B in both groups. Compared with control subjects, asthma was characterized by significantly higher levels of antibodies to RV-A and RV-C, but not RV-B. RV antibody levels positively correlated with the number of common colds over the previous year in healthy children, and wheeze episodes in children with asthma. Antibody levels also positively correlated with asthma severity but not with current asthma control.Conclusions: The variable humoral response to RV species in both groups suggests a differential infectivity pattern between RV species. In healthy preschoolers, RV antibodies accumulate with colds. In asthma, RV-A and RV-C antibodies are much higher and further increase with disease severity and wheeze episodes. Higher antibody levels in asthma may be caused by a compromised innate immune response, leading to increased exposure of the adaptive immune response to the virus. Importantly, there is no apparent protection with increasing levels of antibodies.
Authors: Chloe L McIntyre; E Carol McWilliam Leitch; Carita Savolainen-Kopra; Tapani Hovi; Peter Simmonds Journal: J Virol Date: 2010-07-28 Impact factor: 5.103
Authors: Adnan Custovic; Danielle Belgrave; Lijing Lin; Eteri Bakhsoliani; Aurica G Telcian; Roberto Solari; Clare S Murray; Ross P Walton; John Curtin; Michael R Edwards; Angela Simpson; Magnus Rattray; Sebastian L Johnston Journal: Am J Respir Crit Care Med Date: 2018-05-15 Impact factor: 21.405
Authors: Ann C Palmenberg; David Spiro; Ryan Kuzmickas; Shiliang Wang; Appolinaire Djikeng; Jennifer A Rathe; Claire M Fraser-Liggett; Stephen B Liggett Journal: Science Date: 2009-02-12 Impact factor: 47.728
Authors: Cibele M Gaido; Caitlyn Granland; Ingrid A Laing; Peter N Le Souëf; Wayne R Thomas; Andrew J Currie; Belinda J Hales Journal: Immun Inflamm Dis Date: 2017-11-10
Authors: N G Papadopoulos; I Christodoulou; G Rohde; I Agache; C Almqvist; A Bruno; S Bonini; L Bont; A Bossios; J Bousquet; F Braido; G Brusselle; G W Canonica; K H Carlsen; P Chanez; W J Fokkens; M Garcia-Garcia; M Gjomarkaj; T Haahtela; S T Holgate; S L Johnston; G Konstantinou; M Kowalski; A Lewandowska-Polak; K Lødrup-Carlsen; M Mäkelä; I Malkusova; J Mullol; A Nieto; E Eller; C Ozdemir; P Panzner; T Popov; S Psarras; E Roumpedaki; M Rukhadze; A Stipic-Markovic; A Todo Bom; E Toskala; P van Cauwenberge; C van Drunen; J B Watelet; M Xatzipsalti; P Xepapadaki; T Zuberbier Journal: Allergy Date: 2010-11-18 Impact factor: 13.146
Authors: Debbie J Maurer; Chengyao Liu; Paraskevi Xepapadaki; Barbara Stanic; Claus Bachert; Susetta Finotto; Ya-Dong Gao; Anna Graser; Tuomas Jartti; Walter Kistler; Marek Kowalski; Heikki Lukkarinen; Maria Pasioti; Ge Tan; Michael Villiger; Luo Zhang; Nan Zhang; Mübeccel Akdis; Nikolaos G Papadopoulos; Cezmi A Akdis Journal: Allergy Date: 2021-10-04 Impact factor: 14.710
Authors: Timothy Choi; Mark Devries; Leonard B Bacharier; William Busse; Carlos A Camargo; Robyn Cohen; Gregory P Demuri; Michael D Evans; Anne M Fitzpatrick; Peter J Gergen; Kristine Grindle; Rebecca Gruchalla; Tina Hartert; Kohei Hasegawa; Gurjit K Khurana Hershey; Patrick Holt; Kiara Homil; Tuomas Jartti; Meyer Kattan; Carolyn Kercsmar; Haejin Kim; Ingrid A Laing; Petra LeBeau; Kristine E Lee; Peter N Le Souëf; Andrew Liu; David T Mauger; Carole Ober; Tressa Pappas; Shilpa J Patel; Wanda Phipatanakul; Jacqueline Pongracic; Christine Seroogy; Peter D Sly; Christopher Tisler; Ellen R Wald; Robert Wood; Ronald Gangnon; Daniel J Jackson; Robert F Lemanske; James E Gern; Yury A Bochkov Journal: Am J Respir Crit Care Med Date: 2021-04-01 Impact factor: 30.528
Authors: Petra Pazderova; Eva E Waltl; Verena Niederberger-Leppin; Sabine Flicker; Rudolf Valenta; Katarzyna Niespodziana Journal: Vaccines (Basel) Date: 2020-06-18
Authors: Katarzyna Niespodziana; Katarina Stenberg-Hammar; Nikolaos G Papadopoulos; Margarete Focke-Tejkl; Peter Errhalt; Jon R Konradsen; Cilla Söderhäll; Marianne van Hage; Gunilla Hedlin; Rudolf Valenta Journal: Viruses Date: 2021-05-15 Impact factor: 5.048
Authors: Jacob D Eccles; Ronald B Turner; Nicole A Kirk; Lyndsey M Muehling; Larry Borish; John W Steinke; Spencer C Payne; Paul W Wright; Deborah Thacker; Sampo J Lahtinen; Markus J Lehtinen; Peter W Heymann; Judith A Woodfolk Journal: Cell Rep Date: 2020-01-14 Impact factor: 9.423
Authors: Katarzyna Niespodziana; Kristina Borochova; Petra Pazderova; Thomas Schlederer; Natalia Astafyeva; Tatiana Baranovskaya; Mohamed-Ridha Barbouche; Evgeny Beltyukov; Angelika Berger; Elena Borzova; Jean Bousquet; Roxana S Bumbacea; Snezhana Bychkovskaya; Luis Caraballo; Kian Fan Chung; Adnan Custovic; Guillermo Docena; Thomas Eiwegger; Irina Evsegneeva; Alexander Emelyanov; Peter Errhalt; Rustem Fassakhov; Rezeda Fayzullina; Elena Fedenko; Daria Fomina; Zhongshan Gao; Pedro Giavina-Bianchi; Maia Gotua; Susanne Greber-Platzer; Gunilla Hedlin; Natalia Ilina; Zhanat Ispayeva; Marco Idzko; Sebastian L Johnston; Ömer Kalayci; Alexander Karaulov; Antonina Karsonova; Musa Khaitov; Elena Kovzel; Marek L Kowalski; Dmitry Kudlay; Michael Levin; Svetlana Makarova; Paolo Maria Matricardi; Kari C Nadeau; Leyla Namazova-Baranova; Olga Naumova; Oleksandr Nazarenko; Paul M O'Byrne; Faith Osier; Alexander N Pampura; Carmen Panaitescu; Nikolaos G Papadopoulos; Hae-Sim Park; Ruby Pawankar; Wolfgang Pohl; Harald Renz; Ksenja Riabova; Vanitha Sampath; Bülent E Sekerel; Elopy Sibanda; Valérie Siroux; Ludmila P Sizyakina; Jin-Lyu Sun; Zsolt Szepfalusi; Tetiana Umanets; Hugo P S Van Bever; Marianne van Hage; Margarita Vasileva; Erika von Mutius; Jiu-Yao Wang; Gary W K Wong; Sergii Zaikov; Mihaela Zidarn; Rudolf Valenta Journal: J Allergy Clin Immunol Date: 2020-02-18 Impact factor: 14.290